Pfizer (PFE) closed the most recent trading day at $42.99, moving -1.22% from the previous trading session. This change lagged the S&P 500's daily gain of 0.63%. At the same time, the Dow added 0.68%, and the tech-heavy Nasdaq gained 0.64%.
Heading into today, shares of the drugmaker had lost 3.89% over the past month, outpacing the Medical sector's loss of 3.98% and the S&P 500's loss of 4.95% in that time.
PFE will be looking to display strength as it nears its next earnings release, which is expected to be January 29, 2019. The company is expected to report EPS of $0.64, up 3.23% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $13.91 billion, up 1.52% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $3 per share and revenue of $53.40 billion. These results would represent year-over-year changes of +13.21% and +1.62%, respectively.
It is also important to note the recent changes to analyst estimates for PFE. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.48% higher. PFE is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that PFE has a Forward P/E ratio of 14.51 right now. Its industry sports an average Forward P/E of 14.5, so we one might conclude that PFE is trading at a premium comparatively.
Investors should also note that PFE has a PEG ratio of 2.19 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.98 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
To read this article on Zacks.com click here.